Praluent

German court blocks sale of Sanofi, Regeneron cholesterol drug
German court blocks sale of Sanofi, Regeneron cholesterol drug
Biopharma Dive
patents
Amgen
Sanofi
Regeneron
Germany
Praluent
Repatha
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Praluent's lower list price isn't yielding better sales yet
Praluent's lower list price isn't yielding better sales yet
Biopharma Dive
Sanofi
Regeneron
Praluent
drug pricing
Flag link:
U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
Yahoo/Reuters
Regeneron
Sanofi
Praluent
MACE
FDA
Flag link:
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Regeneron
Sanofi
Amgen
Praluent
Repatha
drug pricing
PCSK9 inhibitors
Flag link:
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Are These Disappointing Drugs Back on Track to Billions?
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
Praluent
Repatha
Flag link:
3 Reasons Regeneron Stock Could Start Climbing Again
3 Reasons Regeneron Stock Could Start Climbing Again
Yahoo/Motley Fool
Sanofi
Regeneron
Praluent
Dupixent
Eylea
Flag link:
Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price
Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price
Xconomy
Regeneron
Sanofi
Express Scripts
PBMs
Praluent
drug pricing
Flag link:
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Amgen
Repatha
Sensipar
generics
Sanofi
Regeneron
Praluent
Flag link:
Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?
Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?
Yahoo/Reuters
Regeneron
Sanofi
Praluent
insurers
clinical trials
Flag link:
Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives
Regeneron to Slash Price of Cholesterol Drug After Showing it Saved Lives
Xconomy
Regeneron
cholesterol
drug pricing
Sanofi
Praluent
Flag link:
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
Forbes
cholesterol
PCSK9 inhibitors
Sanofi
Regeneron
Praluent
Amgen
Repatha
Flag link:
PCSK9 court saga drags on for Sanofi, Regeneron and Amgen
PCSK9 court saga drags on for Sanofi, Regeneron and Amgen
Biopharma Dive
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
Praluent
Repatha
Flag link:
U.S. court reverses ban on sale of Sanofi, Regeneron drug Praluent
U.S. court reverses ban on sale of Sanofi, Regeneron drug Praluent
Yahoo/Reuters
Sanofi
Regeneron
Praluent
Repatha
patents
Flag link:
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Fierce Pharma
Sanofi
Amgen
PCSK9 inhibitors
diabetes
Regeneron
Praluent
Repatha
Flag link:
Insurers, doctors battle over new heart disease drugs
Insurers, doctors battle over new heart disease drugs
CNBC
insurers
cardiovascular disease
statins
PCSK9 inhibitors
Amgen
Regeneron
Sanofi
Repatha
Praluent
Flag link:
In cost debate, Amgen stands by Repatha's value
In cost debate, Amgen stands by Repatha's value
BioPharma Dive
Amgen
Repatha
drug pricing
PCSK9 inhibitors
Praluent
Sanofi
Regeneron
Flag link:
Regeneron’s Praluent May See Gradual Increase in 2017 Demand
Regeneron’s Praluent May See Gradual Increase in 2017 Demand
Market Realist
Regeneron
Praluent
Sanofi
Flag link:
Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics
Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics
Fierce Pharma
Sanofi
Regeneron
Praluent
diabetes
LDL cholesterol
Flag link:

Pages